PolyPeptide Group
Torrance, CA · Strasbourg, FR · Malmo, SE
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
77.7
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
○ MHRA GMP
Quick Facts: PolyPeptide Group
- Signal Score
- 77.7/100 (as of 2026-04-02)
- Quality Compliance
- 98.5/100
- Headquarters
- Torrance, CA · Strasbourg, FR · Malmo, SE
- Modalities
- Oligonucleotide
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
98.5
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-05-15)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
61.0
Private company
Financial assessment: 61.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 61.0/100
Capacity
58.0
3 manufacturing sites
Sites: Torrance, CA, Strasbourg, FR, Malmo, SE
Source: SEC EDGAR, press monitoring, company profiles
3 manufacturing sites
Recent Press3 articles
3 manufacturing sites
FDA Inspection History
2025-05
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-05-15 | San Diego, California | Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Apr 05, 2026
Recent News 3 articles
PolyPeptide publishes invitation to the annual General Meeting 2026 - TradingView
PolyPeptide publishes invitation to the annual General Meeting 2026 TradingView
PolyPeptide Group / CH1110760852 - AD HOC NEWS
PolyPeptide Group / CH1110760852 AD HOC NEWS
PolyPeptide delivers strong revenue growth and marked improvement in profitability - TradingView
PolyPeptide delivers strong revenue growth and marked improvement in profitability TradingView
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 81.6
mRNA, Oligonucleotide, Biologics
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.4
mRNA, Oligonucleotide, Biologics
TriLink BioTechnologies
San Diego, CA
Signal Score: 71.0
mRNA, Oligonucleotide
LGC Biosearch Technologies
Petaluma, CA · Middleton, WI
Signal Score: 63.0
Oligonucleotide